---
schema_version: "secwatch.filing_event.v1"
accession: "0000805928-26-000091"
form_type: "8-K"
ticker: "AXGN"
cik: "0000805928"
company_name: "Axogen, Inc."
filed_at: "2026-07-29T11:11:02+00:00"
generated_at: "2026-07-29T11:15:13.441316+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Axogen Q2 revenue $69.7M (+23% YoY), raises FY2026 guidance to at least $279M (24% growth)

## Summary
- Revenue $69.7M, up 23.1% YoY; net loss $1.5M ($0.03/sh) vs net income $0.6M ($0.01/sh) in Q2 2025.
- Adjusted net income $7.3M ($0.12/sh) vs $5.7M ($0.12/sh) YoY; adjusted EBITDA $8.4M vs $9.3M.
- Raises FY2026 revenue guidance to at least $279M (24% growth); gross margin guidance at least 73%; expects positive free cash flow.
- Gross margin 72.7% vs 74.2% due to product mix shift from >50% Breast growth.
- Cash and investments $113.4M, up $9.8M from Q1 2026; minority stake in Trace Biosciences.

## SEC filing metadata
- accession: 0000805928-26-000091
- form_type: 8-K
- ticker: AXGN
- cik: 0000805928
- company_name: Axogen, Inc.
- filed_at: 2026-07-29T11:11:02+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/805928/000080592826000091/0000805928-26-000091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/805928/000080592826000091/axgn-20260729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000805928-26-000091
- JSON: https://secwatch.observer/filing/0000805928-26-000091.json
- Plain text: https://secwatch.observer/filing/0000805928-26-000091.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.